Towards wafer scale inductive determination of magnetostatic and dynamic parameters of magnetic thin films and multilayers

We investigate an inductive probe head suitable for non-invasive characterization of the magnetostatic and dynamic parameters of magnetic thin films and multilayers on the wafer scale. The probe is based on a planar waveguide with rearward high frequency connectors that can be brought in close contact to the wafer surface. Inductive characterization of the magnetic material is carried out by vector network analyzer ferromagnetic resonance. Analysis of the field dispersion of the resonance allows the determination of key material parameters such as the saturation magnetization MS or the effective damping parameter Meff. Three waveguide designs are tested. The broadband frequency response is characterized and the suitability for inductive determination of MS and Meff is compared. Integration of such probes in a wafer prober could in the future allow wafer scale in-line testing of magnetostatic and dynamic key material parameters of magnetic thin films and multilayers

Emissions Savings in the Corn-Ethanol Life Cycle from Feeding Coproducts to Livestock

Environmental regulations on greenhouse gas (GHG) emissions from corn (Zea mays L.)-ethanol production require accurate assessment methods to determine emissions savings from coproducts that are fed to livestock. We investigated current use of coproducts in livestock diets and estimated the magnitude and variability in the GHG emissions credit for coproducts in the corn-ethanol life cycle. The coproduct GHG emissions credit varied by more than twofold, from 11.5 to 28.3 g CO2e per MJ of ethanol produced, depending on the fraction of coproducts used without drying, the proportion of coproduct used to feed beef cattle (Bos taurus) vs. dairy or swine (Sus scrofa), and the location of corn production. Regional variability in the GHG intensity of crop production and future livestock feeding trends will determine the magnitude of the coproduct GHG offset against GHG emissions elsewhere in the corn-ethanol life cycle. Expansion of annual U.S. corn-ethanol production to 57 billion liters by 2015, as mandated in current federal law, will require feeding of coproduct at inclusion levels near the biological limit to the entire U.S. feedlot cattle, dairy, and swine herds. Under this future scenario, the coproduct GHG offset will decrease by 8% from current levels due to expanded use by dairy and swine, which are less efficient in use of coproduct than beef feedlot cattle. Because the coproduct GHG credit represents 19 to 38% of total life cycle GHG emissions, accurate estimation of the coproduct credit is important for determining the net impact of corn-ethanol production on atmospheric warming and whether corn-ethanol producers meet state- and national-level GHG emissions regulations

C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance

Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5–18.8%), although estimates in individual studies exhibited significant heterogeneity, P< 0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51–2.78) and RR = 1.74 (95% CI = 1.27–2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. © 2000 Cancer Research Campaign http://www.bjcancer.co

A simple quality improvement program improves cardiovascular preventive care offered by medical housestaff at a large, urban hospital treating a high-risk inpatient population

L'edifici fou construït l'any 1850, aproximadament.Primer pla, contrapicat, d'un edifici d'habitatges entre mitgeres. Consta de planta baixa, cinc plantes pis i coberta terrat. La composició de la façana té un eix de simetria vertical central, que coincideix amb la posició de l'escala de veïns

Electromagnetic Simulation and Design of a Novel Waveguide RF Wien Filter for Electric Dipole Moment Measurements of Protons and Deuterons

The conventional Wien filter is a device with orthogonal static magnetic and electric fields, often used for velocity separation of charged particles. Here we describe the electromagnetic design calculations for a novel waveguide RF Wien filter that will be employed to solely manipulate the spins of protons or deuterons at frequencies of about 0.1 to 2 MHz at the COoler SYnchrotron COSY at J\"ulich. The device will be used in a future experiment that aims at measuring the proton and deuteron electric dipole moments, which are expected to be very small. Their determination, however, would have a huge impact on our understanding of the universe.Comment: 10 pages, 10 figures, 4 table

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.

A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice